H&Q Life Sciences Investors (AMEX:HQL)
A business trust registered as a diversified, closed-end management investment company.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Covestor Model Manager Dan Plettner Bought HQL in his Taxable Income Covestor Model ( http://covestor.com/Dan-Plettner )
Recs
brought there div back 5%
Recs
Foolish pick - 10/09
Recs
Diversified potential
Recs
Um, lets see, sales growth -73%. And their income is -50 times more than sales.? They will be a fraction of a penny stock soon im sure
Recs
Trading at 20.5% discount to NAV
Recs
Stock has shown some strength of late---maybe reflecting the renewed interest in consolidation in the industry.
Recs
This stock was picked by TMFBean in the 2008 TMF Stockpicking Contest.
Recs
A good way to get into biotech and manage your risk. Growth potential with a solid dividend makes this a great investment for a longer period.
Recs
Now trades at big discount. Sector is promising, and defensive.
Recs
Dividends are not enough to offset the risk of a "basket" of stocks having too many losers. Biotech requires picking the right stocks and ignoring all the fluff, which is why I don't go there any more. I have no competency in the field and not interested in the extensive research needed to pick winners. Even those stocks that have 5 stars from CAPS don't get my attention because I feel the political climate in the US congress today is down on pharmaceuticals. Too many drugs being recalled because of serious side effects in the news. Will be tougher to get anything approved in the next few years. Good luck to those of you who pick the right ones and get the 10 baggers!
Recs
stock of the week pick
Recs
A nice ETF that is diversified on micro ans small cap biotech firms. It pays a regular dividend that is > 4%
Recs
Baby boomers are always aging. This is a lucritive area of science. The more we learn the more there is to learn and new fields of excelence that arise are available for profit.
Recs
Underrated, captures a growing field with less risk.
Recs
Nice, a biotech ETF with a divy and a discount to NAV. I love it.
Recs
My first ETF. Let's see what goes on.
Recs
going with the 8% and recommendations coming out for this
Recs
Its all about demographics. Difficult not to make money with it, and well diversified as an ETF.
Recs
Health cost is the major concern for the baby boomer.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 25 : 1 2 Next »